Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

Serious infections in patients with myasthenia gravis: population‐based cohort study

(2020) C. D. Kassardjian et al.   EUROPEAN JOURNAL OF NEUROLOGY

ANTIBODIES AND RECEPTORS: From Neuromuscular Junction to Central Nervous System

(2020) Angela Vincent   NEUROSCIENCE

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

(2019) James F. Howard et al.   NEUROLOGY

Myasthenia gravis

(2019) Nils Erik Gilhus et al.   Nature Reviews Disease Primers

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans

(2018) Peter Ulrichts et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

(2017) James F Howard et al.   LANCET NEUROLOGY

A Two-pronged Binding Mechanism of IgG to the Neonatal Fc Receptor Controls Complex Stability and IgG Serum Half-life

(2017) Pernille Foged Jensen et al.   MOLECULAR & CELLULAR PROTEOMICS

International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15r

(2016) Ted M. Burns et al.   MUSCLE & NERVE

Myasthenia gravis — autoantibody characteristics and their implications for therapy

(2016) Nils Erik Gilhus et al.   Nature Reviews Neurology

Myasthenia Gravis

(2016) Nils E. Gilhus   NEW ENGLAND JOURNAL OF MEDICINE

Myasthenia gravis: subgroup classification and therapeutic strategies

(2015) Nils Erik Gilhus et al.   LANCET NEUROLOGY

Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates

(2015) Andrew E. Nixon et al.   Frontiers in Immunology

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

(2013) P. Zisimopoulou et al.   JOURNAL OF AUTOIMMUNITY

Antibodies against low-density lipoprotein receptor–related protein 4 induce myasthenia gravis

(2013) Chengyong Shen et al.   JOURNAL OF CLINICAL INVESTIGATION

Endplate contributions to the safety factor for neuromuscular transmission

(2011) Robert L. Ruff   MUSCLE & NERVE

Guidelines for treatment of autoimmune neuromuscular transmission disorders

(2010) G. O. Skeie et al.   EUROPEAN JOURNAL OF NEUROLOGY

Neonatal Fc Receptor: From Immunity to Therapeutics

(2010) Timothy T. Kuo et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice

(2010) R. N. Cole et al.   JOURNAL OF PHYSIOLOGY-LONDON

The MG Composite: A valid and reliable outcome measure for myasthenia gravis

(2010) T. M. Burns et al.   NEUROLOGY

Comparing the Autoantibody Levels and Clinical Efficacy of Double Filtration Plasmapheresis, Immunoadsorption, and Intravenous Immunoglobulin for the Treatment of Late-onset Myasthenia Gravis

(2009) Jun-Feng Liu et al.   THERAPEUTIC APHERESIS AND DIALYSIS

Serum Immunoglobulins and Risk of Infection: How Low Can You Go?

(2008) Daniel E. Furst   SEMINARS IN ARTHRITIS AND RHEUMATISM